Multiple paradoxical adverse events in a patient with ankylosing spondylitis treated with adalimumab.
Clinical Investigation Centre in Biotherapy, INSERM CIC-1431, University Hospital of Besançon,, FHU INCREASE, University Hospital of Besançon,, Department of Rheumatology, University Hospital of Besançon,, Department of Therapeutics and UPRES EA 4266: "Pathogenic agents and Inflammation", University of Franche-Comté
Éric
É
Toussirot
Department of Dermatology, University Hospital of Besançon.
Romain
R
Charollais
Department of Dermatology, University Hospital of Besançon,, EA 3181, SFR 4234, University of Franche-Comté, Besançon, France.
François
F
Aubin
D000038:Abscess / Q000139:chemically induced*; D000068879:Adalimumab / Q000009:adverse effects*; D018501:Antirheumatic Agents / Q000009:adverse effects*; D017577:Cutaneous Fistula / Q000139:chemically induced*; D003875:Drug Eruptions / Q000209:etiology*; D005260:Female; D017497:Hidradenitis Suppurativa / Q000139:chemically induced; D006801:Humans; D011565:Psoriasis / Q000139:chemically induced; D012003:Rectal Fistula / Q000139:chemically induced*; D013167:Spondylitis, Ankylosing / Q000188:drug therapy*; D055815:Young Adult
D018501:Antirheumatic Agents; D000068879:Adalimumab